Latest Insights on CCI
The #1 Breakthrough Biotech Stock for 2023 November 1, 2022 Investment Opportunities, Technology, Trending, Winning Investor Daily
CRISPR Therapeutics is dedicated to 2 things: genetics research and saving lives. find out why this biotech stock is our #1 pick for 2023!
Putting Puts In Perspective; Or, She Sells Options Sanctuary October 28, 2022 Great Stuff
Reader Feedback: The “Put Your Money Where Your Options Are” Edition Great Ones, we received such positive feedback to last Friday’s “Pondering Put Selling” edition of Reader Feedback … that we’re doing it again! Also, I absolutely love reading and responding to your questions and emails … so keep ‘em coming! Drop us a line […]
The 3% of Stocks That Rise in Bear Markets October 19, 2022 Investing, Trading Strategies, True Options Masters
A very small number of stocks do deliver gains in a bear market. Today’s True Options Masters is all about finding those stocks, and figuring out if now’s the time to buy them...
Inflation, Stagflation, CPI Proclamations & Domino’s Pizza Pies? October 13, 2022 Great Stuff
Rocked You Like An Inflation Hurricane Great Ones, it starts with an earthquake … the Consumer Price Index and jobless claims. Lenny Bruce is not afraid… We’re in the eye of an inflation hurricane, but you really shouldn’t listen to yourself churn. The world serves its own needs. Don’t mis-serve your own needs. You need […]
Two Ways to Stem a Bleeding Portfolio October 13, 2022 Investing, Trading Strategies, True Options Masters
We’re all hoping the bear market will end soon. But the reality is, hope is not a plan. The reality is, risks remain high. And acknowledging those risks is the first step to preserving your portfolio...MEET OUR EXPERTS
Founder of Sovereign Man
Research Analyst
Director of VIP Services
Chief Investment Strategist of Money & Markets
Early in his career, Shad cut his teeth in the world of music marketing [...]
Editor of Alpha Investor
Editor of Strategic Fortunes and three elite services
Financial Analyst
Founder, Agora
